medigraphic.com
ISSN 1527-3172 (Electronic)

2009, Number 3

<< Back Next >>

MEDICC Review 2009; 11 (3)

Clinical experience with Nimotuzumab in cuban pediatric patients with brain tumors, 2005 to 2007

Saurez G, Cabanas R, Zaldívar M, Garnier T, Iglesias B, Piedra P, Ríos CM, Longchong M, Iznaga N, Lage A

Language: English
References: 41
Page: 27-33
PDF size: 518.51 Kb.


ABSTRACT

Introduction Nimotuzumab, developed in Cuba, is a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It has been evaluated in malignant brain tumors in adults and children, and shown to be therapeutically safe and effective in terms of increased survival and improved quality of life.
Objective Describe nimotuzumab’s safety profile and clinical benefits in terms of disease control and survival in pediatric patients with progressive or recurrent primary brain tumors who were included in an expanded access program.
Methods An open, prospective clinical study was designed. Between December 2005 and December 2007, 22 patients were included, all of whom had an histological and/or radiological diagnosis of progressive or recurrent primary brain tumor, classified as high-grade malignant glioblastoma (n=6), diffuse brain stem glioma (n=6), ependymoblastoma (n=5), low-grade glioma (n=4), or thalamic tumor (n=1); life expectancy of at least 4 weeks; and a Karnofsky or Lansky Performance Status score of ≥50. Nimotuzumab was administered on a 100 mg weekly intravenous infusion schedule for 6 to 8 weeks, followed by a bi-weekly maintenance phase, as long as there was no deterioration in the patient’s functional capacity. Therapeutic protocols were followed for administration as monotherapy or in combination with chemotherapy and/or radiotherapy. All patients received clinical and imaging follow-up.
Results Nimotuzumab was well tolerated in all therapeutic modalities, even with prolonged exposure. A minority of patients reported slight or moderate adverse events, such as vomiting, mucositis and chills, as classified by the Common Terminology Criteria for Adverse Events (CTCAE). The disease was controlled in 64% (14/22) of patients; 6-month and 1-year survival rates were 82% and 64%, respectively; average survival was 20.3 months and median survival, 19 months. Recovery of neurological functions and improvement in general status were notable in patients who attained control of the disease.
Conclusions As used in this study, nimotuzumab demonstrated a broad safety profile, making it acceptable for chronic use, and implied clinical benefits in terms of increased survival and improved functional status in these patients, compared to findings described in the literature. These results indicate further studies of this product are warranted.


REFERENCES

  1. Strother DR, Pollack IF. Tumors of the Central Nervous System. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincot Williams and Wilkins; 2002. p. 751–814.

  2. Lanskoswky P. Manual of Pediatric Hematology Oncology. San Diego: Academic Press; 2000. p. 471–91.

  3. Wilne S, Collier J, Kennedy C, Koler K, Grundy R, Walker D. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007 Aug;8(8):685–95.

  4. Taquechel CO, Corral N, Verdecia M, Legrá R, Psudides A. Tumores del sistema nervioso central en la infancia. MEDISAN. 2003;7(4):30–4.

  5. Packer RJ. CNS tumors. In: Agarwal B, Perilongo G, Calaminus G, Eden T, editors. SIOP Education Book; 2007.

  6. Jahraus CD, Tarbell NJ. Optic Pathway Gliomas. Pediatr Blood Cancer. 2006 May 1; 46(5):586– 96. Review.

  7. Broniscer A, Gajjar A. Supratentorial High Grade Astrocitomas and Difusse Brain Stem Glioma: Two Challenges for the Pediatric Oncologist. Oncologist. 2004;9(2):197–206.

  8. Macdonald TJ, Rood BR, Santi MR, Vezina G, Bingaman K, Cohen PH, et al. Advances in the Diagnosis, Molecular Genetics and Treatment of Pediatric Embryonal CNS Tumors. Oncologist. 2003;8(2):174–86.

  9. Packer RJ, Gurney JG, Punyko JA, Donaldson SS, Inskip PD, Stovall M, et al. Long term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J Clin Oncol. 2003 Sep 1;21(7):3255–61.

  10. Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical and futuristic perspective. J Neurooncol. 2005 Dec;75(3):253–66.

  11. Bowers DC, Gargan L, Weprin BE, Mulne AF, Elterman RD, Munoz L, et al. Impact of site of tumor recurrence upon survival for children with recurrent or progressive medulloblastoma. J Neurosurg. 2007 Jul;107(1 Suppl):5–10.

  12. Packer Roger J. Progress and challenges in childhood brain tumors. J Neurooncol. 2005 Dec;75(3):239–42.

  13. Warren KE. Molecularly targeted therapy for pediatric brain tumors. J Neurooncol. 2005 Dec;75(3):335–43.

  14. Basel J. Targeting tyrosine kinases in cancer: the second wave. Science. 2006 May 26;312(5777):1175–8.

  15. Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Pérez R. Humanization of a mouse monoclonal antibody that blocks the Epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology. 1997 May;3(1):71–81.

  16. World Health Organization Drug Information. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94. 2005;19(4):333.

  17. Crombet T, Torres O, Rodríguez V, Menéndez A, Stevenson A, Ramos M, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor in advanced brain tumor patients. Hybridoma. 2001;20(2):131–36.

  18. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003 Apr;26(2):139–48.

  19. Crombet T, Osorio M, Cruz T, Roca C, Del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646–54.

  20. Crombet T, Figueredo J, Catalá M, González S, Selva JC, Cruz TM, et al. Treatment of highgrade glioma patients with the humanized antiepidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5(4):375–9.

  21. Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol. 2007;25(18 Suppl):S2006.

  22. Bode U, Windelberg M, Massimino M, Khuhlaeva E, Warmuth-Metz M, Kortmann R, et al. Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. J Clin Oncol. 2008;26(15 Suppl):S2058.

  23. Brade AM, Siu L, Oza AM, Southwood B, De Borja M, Pond G, et al. A phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) TheraCIM-h-R3 (Nimotuzumab) in patients with advanced solid tumors. J Clin Oncol. 2006;24(18 Suppl):S13054.

  24. Bebb DG, Brade AM, Smith C, Rorke S, Sherman I. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. J Clin Oncol. 2008;26(15 Suppl):S3037.

  25. Xiao-Dong H, Guo-Zhen X, Lil G, Jun-Lin Y, Tai-Xiang L, Shao-Xiong W, et al. Multi-center Phase II Clinical Trial of h-R3, the Recombined Humanized Anti-Epidermal Factor Receptor Monoclonal Antibody, in Combination with Radiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Chin J Oncol. 2007;29(3):197–201.

  26. ClinicalTrials.gov [homepage on the Internet]. YM Biosciences;[updated 2009 June 3; cited 2009 Feb]. Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma. Available from: http://www.clinicaltrial.gov/ ct2/show/NCT00600054.

  27. Ramakrishnan MS, Eswariah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009 Jan– Feb;1(1):41–8.

  28. Reddy BK, Vidyasagar M, Shenoy K, Shenoy A, Viswanath L, Babu G, et al. BIOMAb EGFRTM (Nimotuzumab/h-r3) in Combination with standard of care in squamous cell carcinoma of head and neck (SCCHN). Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S450.

  29. Pendharkar D, Gupta S, Pal MK, Hakim S, Rashid T. Feasibility of combining humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 (nimotuzumab) with chemotherapy- A study of toxicity profile and tolerance. J Clin Oncol. 2007;25(18 Suppl):S14151.

  30. Bebb DG, Brade AM, Smith C, Rorke S, Sherman I. Preliminary results of an escalating dose phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIb, III or IV nonsmall cell lung cancer unsuitable for radical therapy. J Clin Oncol. 2008 May;26 (15 Suppl):S3037.

  31. ClinicalTrials.gov [homepage on the Internet]. YM Biosciences;[updated 2009 Jan 15; cited 2009 Jan 15]. Iressa expanded access Program program. Available from: http://clinicaltrials.gov/ show/NCT00034879

  32. Okie S. Access before Approval- A Right to Take Experimental Drugs? N Engl J Med. 2006 Aug 3;355(5):437–40.

  33. Guideline on compassionate use of medicinal products, pursuant to article 83 of regulation (ec) no 726/2004. London, 19 July 2007. Doc. Ref: EMEA/27170/2006.

  34. Ünal E, Sahdev I. Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed/refractory Acute Myeloid Leukemia. Turk J Hematol. 2008 Mar;25(1):36–41.

  35. National Cancer Institute [Internet]. Rockville (MD): Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS (US);[updated 2008 May 29; cited 2003 Mar 31]. Available from: http://ctep.cancer.gov.

  36. Zeltzer PM, Friedman HS, Norris DG, Ragab AH. Criteria and definition of response and relapse in children with brain tumor. Cancer. 1985;56(7 Suppl):S1824–6.

  37. Ciardiello F, Tortora G. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Investing Drugs. 2002 Jun;11(6):755–68.

  38. Crombet T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, anti-angiogenic and proapoptotic activity of h-R3: A Humanized anti-EGFR antibody. Int J Cancer. 2002 Oct 20;101(6):567–75.

  39. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE). J Clin Oncol. 2008 Nov 20;26(33):5326–34.

  40. Metro G, Mottolese M, Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin Pharmacother. 2008 Oct;9(15):2583–601.

  41. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin’s Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23(6):1088–95




2020     |     www.medigraphic.com